Results 121 to 130 of about 13,289,433 (300)
FlexMat, EarlyView.Centered on the multiscale meniscus, this review dissects mass transport in meniscus‐guided coating into parallel and lateral components. By analyzing the balance of multiple factors during crystallization, it establishes a clear morphology‐performance relationship.
Yumeng Wang +7 more
wiley +1 more source
Food Biomacromolecules, EarlyView.This review synthesizes 94 studies (2000–2025) exploring edible insects as sustainable sources of peptides, lipids, and chitin. Utilizing “green” extraction, these bioactives offer antioxidant and antimicrobial benefits for functional foods. However, addressing safety concerns like allergenicity and heavy metals through standardized frameworks remains ...
Blessing Rachael Adeyeye +1 more
wiley +1 more source
, 2016 Unchalee Permsuwan,1 Piyameth Dilokthornsakul,2 Surasak Saokaew,2–4 Kednapa Thavorn,5–7 Nathorn Chaiyakunapruk2,4,8,9 1Faculty of Pharmacy Chiang Mai University, Chiang Mai, 2Center of Pharmaceutical Outcomes Research, Faculty of ...
Chaiyakunapruk N +4 more
core
Food Safety and Health, EarlyView.Withania somnifera seed extract and powder improved metabolic parameters in rats, particularly at higher extract doses, without evident hepatic, renal, hematological, or histopathological toxicity. Molecular docking further predicted strong DPP‐4 inhibitory potential of withanone, supporting the antidiabetic potential of W. somnifera seeds.
Muhammad Usman Khalid +8 more
wiley +1 more source
Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes
Diabetes, Metabolic Syndrome and Obesity, 2013 Baptist GallwitzDepartment of Medicine IV, Eberhard-Karls-University Tübingen, Tübingen, GermanyAbstract: The first dipeptidyl-peptidase-IV (DPP-4) inhibitor for the treatment of type 2 diabetes became available in 2006. Since then, the
Gallwitz B
doaj
Screening Emodin Derivatives as DPP-4 Inhibitor Candidates: In Silico and In Vitro Assessment [PDF]
Diabetes mellitus (DM) is a chronic metabolic disease distinguished by disrupted glucose metabolism, causing elevated blood sugar levels. One of the latest therapeutic strategies involves inhibiting dipeptidyl peptidase-4 (DPP-4) to regulate glucose ...
Syahbirin, Gustini +3 more
core +1 more source
International Journal of Cancer, EarlyView.ABSTRACT This multicenter retrospective study evaluated the impact of type 2 diabetes mellitus (DM) on clinical outcomes and immune‐related adverse events (irAEs) in 450 patients with metastatic non‐small cell lung cancer (NSCLC) treated with second‐line nivolumab at 17 centers between 2016 and 2024. Among these patients, 118 (26.2%) had DM.
Emre Çakır +32 more
wiley +1 more source
Role of DPP-4 inhibitors in the treatment of type 2 Diabetes
, 2014 Dipeptidyl peptidase 4 (DPP-4) inhibitors are a relatively new class of oral anti-hyperglycaemic medication which enhance insulin secretion. They are considered to be a promising drug class that may meet the demands for efficacy in the treatment of type ...
Nguyen, Khanh Minh
core
DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS
, 2016 Diabetes mellitus (DM) is a chronic disease which caused around 1.5 million deaths in 2012. Type 2 diabetes mellitus (T2DM) accounts for 90% of DM worldwide. The prevalence of T2DM is increasing due to obesity.
Kristin, Erna
core +1 more source
Overcoming spectral limits of perovskite photodetectors for the infrared region
InfoScience, EarlyView.Infrared (IR) photodetectors are vital for modern optoelectronics, but traditional inorganic semiconductors face limitations in cost, processing, and bandgap tunability. This review provides a summary of advanced strategies to extend metal halide perovskites into the IR region, categorizing approaches into intrinsic material engineering, physical ...
Jiean Li +4 more
wiley +1 more source